Julie joined GSK and was appointed as Chief Financial Officer Designate on 3 April 2023. She was appointed to the Board as Chief Financial Officer on 1 May 2023. She is a member of the GSK Leadership Team.
Prior to joining GSK, Julie was Chief Operating and Financial Officer and Executive Director, Burberry Group plc. Julie has an extensive life sciences background having been the Group CFO of Smith & Nephew from 2013 to 2017 and serving as a Non-Executive Director and Audit Chair of Roche Holding AG from 2016 to 2022. Before this, Julie was Interim Group CFO of AstraZeneca, having worked at the company for 25 years in finance, commercial and strategic roles in four countries and across three continents.
Julie is a Fellow of the Institute of Chartered Accountancy and the Institute of Tax. She qualified with KPMG International Limited.
External appointments:
- Co-Chair, CFO Leadership Network, Accounting for Sustainability (part of The Prince of Wales’s Charitable Foundation)
- Member, Business Advisory Board to the Mayor of London
- Patron, Oxford University Women in Business
- Member, The 100 Group
